Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
Rhea-AI Summary
Serina Therapeutics (NYSE American: SER) announced a CEO presentation and live Q&A titled “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences” on Wednesday, February 4, 2026 at 8:30 AM PT / 11:30 AM ET.
CEO Steven Ledger will discuss potential FDA impacts on drug development timelines and review processes; registration is complimentary at New-FDA-Era.TribePublic.com and questions can be submitted to research@tribepublic.com or via Zoom chat.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SER gained 1.47%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.8% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $471K to the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SER is down 16.31% while key biotech peers like VTVT (+6.12%), JUNS (+11.28%), PYPD (+7.03%), and RLMD (+9.12%) trade higher, indicating stock-specific pressure rather than a sector-wide move. MAIA is an outlier at -17.8%.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 28 | IND clearance | Positive | -0.7% | FDA cleared IND for SER-252, enabling Phase 1b registrational study. |
| Jan 15 | Listing deficiency notice | Negative | +0.8% | NYSE American notified company of noncompliance with equity standards. |
| Dec 11 | Executive hire | Positive | -2.2% | Appointed VP, Head of Chemistry to support POZ-based candidates and SER-252. |
| Dec 10 | Clinical hold response | Positive | -3.0% | Submitted complete response to FDA clinical hold for SER-252 program. |
| Nov 13 | Earnings & update | Neutral | -2.5% | Reported Q3 2025 results, 505(b)(2) pathway, clinical hold, and financing. |
Recent history shows frequent divergences: multiple positive or constructive updates have been followed by negative price reactions, while clearly negative listing news saw a small gain.
Over the past few months, Serina has focused on advancing its SER-252 Parkinson’s program and shoring up finances. The FDA clinical hold disclosed in Nov 2025 was followed by a complete response submission on Dec 9, 2025 and eventual IND clearance on Jan 28, 2026 to begin a Phase 1b registrational study. Financially, the company reported Q3 2025 results, detailed a $20.0M convertible note and ATM usage, then received an NYSE American equity deficiency notice on Jan 15, 2026. Today’s webinar announcement fits into an ongoing effort to communicate strategy during this transition period.
Regulatory & Risk Context
An effective S-3 shelf dated 2026-01-30 registers 7,722,006 common shares for resale tied to a 2025 senior unsecured convertible note and warrants. The company will not receive proceeds from these resales, although the underlying note provides up to $20 million of funding at 10% interest, convertible at $5.18 per share with warrants exercisable at $5.44. Filings highlight going-concern doubts, NYSE American equity deficiency, and early-stage clinical risk.
Market Pulse Summary
This announcement highlights Serina’s plan for a February 4, 2026 CEO webinar focused on FDA’s 2026 priorities and their impact on life sciences. Set against recent milestones—IND clearance for SER-252 on Jan 28, 2026, an NYSE American equity deficiency notice, and an S-3 registering 7,722,006 shares tied to a $20 million note—the event serves as additional engagement rather than a new clinical or financial catalyst. Investors may watch for updates on trial execution, listing compliance, and financing strategy.
Key Terms
fda regulatory
AI-generated analysis. Not financial advice.
“Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences"
Featuring Serina Therapeutics’ CEO - Wednesday, February 4, 2026
- Hear how FDA initiatives in 2026 may impact drug development timelines, review processes, and investor expectations across the life sciences sector
- Meet with Serina’s CEO Steven Ledger
- Register at New-FDA-Era.TribePublic.com
HUNTSVILLE, AL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, is pleased to announce that Serina’s CEO, Steven Ledger will present at Tribe Public’s Webinar Presentation and Q&A Event titled “Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences". The Event is scheduled to begin at 8:30 am pacific / 11:30 am eastern on Wednesday, February 4, 2026. To register to join the complimentary event, please visit the Tribe Public LLC at New-FDA-Era.TribePublic.com.
Once registered, participants may begin forwarding their questions for the CEO to Tribe Public at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public’s Managing Member, John F. Heerdink, Jr., will host the event and relay all questions to management.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com.
About Tribe Public LLC
Tribe Public LLC, headquartered in San Francisco, California, is a distinguished organization that facilitates corporate sponsored global webinars and in-person meetings events across 41 premier event venues throughout the United States. Tribe Public’s events are tailored to address topics of significant interest to its members, with a particular emphasis on providing direct access to management teams and leading experts from diverse sectors who seek to enhance awareness of their products, achievements, and strategic initiatives. The Tribe’s membership is composed primarily of Family Offices, Portfolio Managers, Registered Investment Advisors, Accredited Investors, Sell Side Analysts, and media professionals, all of whom benefit from exclusive opportunities for business development, community building, and informed dialogue in a collegial setting. Members are actively encouraged to shape the event agenda by submitting speaker and company preferences through Tribe Public’s complimentary “Wish List” process on its website, ensuring that the programming reflects the evolving interests of its sophisticated community. To learn more about Tribe Public’s offerings and to participate in upcoming events, visit their website at: http://www.tribepublic.com/
Cautionary Statement Regarding Forward-Looking Statement
References in this Report to “Serina,” “the Company,” “we” or “us” refer to Serina Therapeutics, Inc. This release contains forward-looking statements within the meaning of federal securities laws. All statements that are not historical fact, including statements about the Company’s response to the FDA’s clinical hold letter, Serina’s planned clinical programs, including timing for first-patient-in and resolution of the clinical hold and customary regulatory and ethics approvals, the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Undue reliance should not be placed on these forward-looking statements which speak only as of the date they are made, and the facts and assumptions underlying these statements may change.
Actual results may differ materially from those projected in such statements due to a variety of important factors including, among other things, the timing and extent of the FDA's clinical-hold letter and of Serina's response, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; Serina’s ability to continue as a going concern; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC. The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
When is Serina Therapeutics (SER) CEO Steven Ledger presenting at the Tribe Public webinar?
How can investors register for Serina Therapeutics (SER) CEO webinar on February 4, 2026?
What topics will Serina Therapeutics (SER) cover in the "Navigating the New FDA Era" webinar?
Can shareholders ask questions during Serina Therapeutics (SER) CEO's Tribe Public presentation?
Who is hosting the Serina Therapeutics (SER) webinar and how will questions be managed?
